Toronto

The trials here

What the 63 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia7 trials
• Lung cancer7 trials
• Childhood cancers6 trials
• Prostate cancer5 trials
• Lupus (SLE)4 trials
• Melanoma4 trials
• Metastatic breast cancer4 trials
• Acute myeloid leukaemia3 trials
• Colorectal cancer3 trials
• Coronary artery disease3 trials
• Gastric and oesophageal cancer3 trials
• Myelodysplastic syndromes3 trials
• and 35 more

Phase

• Phase 328 trials
• Phase 214 trials
• Phase 111 trials
• Phase 1/24 trials
• Phase 43 trials

Status

• Active, not recruiting25 trials
• Completed16 trials
• Recruiting14 trials
• Terminated8 trials

Lead sponsor

• Novartis Pharmaceuticals63 trials

Running trials

• Recruiting

  A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

  NCT07775924· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

  NCT07604571· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

  NCT07570979· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

  NCT07431177· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  NCT07288359· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Real-world Secukinumab Outcomes in Canadian HS Patients

  NCT07282015· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT07220577· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

  NCT07217067· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

  NCT06858319· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  NCT06726148· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Modifying PEST for Psoriatic Arthritis Screening

  NCT06382051· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  NCT06562192· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

  NCT06247995· Phase 1/2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

  NCT05849298· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

  NCT05513001· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

  NCT05456191· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

  NCT05544929· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05349214· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT04971226· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Pediatric Long-Term Follow-up and Rollover Study

  NCT03975829· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

  NCT03814746· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

  NCT03876769· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

  NCT03333343· Phase 1· Novartis Pharmaceuticals· Source

• Recruiting

  Dabrafenib and/or Trametinib Rollover Study

  NCT03340506· Phase 4· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

  NCT02393625· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

  NCT02381886· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Prostate cancer3 recruiting
• Childhood cancers2 recruiting
• Metastatic breast cancer2 recruiting
• Atrial fibrillation1 recruiting
• Colorectal cancer1 recruiting
• Hidradenitis suppurativa1 recruiting
• IgA nephropathy1 recruiting
• Lichen planus1 recruiting
• Melanoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Triple-negative breast cancer1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

  NCT05032157· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

  NCT04948333· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

  NCT04541589· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

  NCT04278417· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

  NCT04150029· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

  NCT03774082· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Out of Specification for Tisagenlecleucel

  NCT04094311· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Terminated

  Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

  NCT04097821· Phase 1/2· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

  NCT03798626· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

  NCT03785405· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

  NCT03114319· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

  NCT02936102· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

  NCT02900651· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  A Registry of Patients With Moderate to Severe Plaque Psoriasis

  NCT02786186· Novartis Pharmaceuticals· Source

• Completed

  LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

  NCT01828112· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

  NCT01698905· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

  NCT00680901· Phase 3· Novartis Pharmaceuticals· Source